• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cisco, Bath & Body Works And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

    11/17/22 6:14:08 AM ET
    $ARDX
    $BBWI
    $CIG
    $CSCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Get the next $ARDX alert in real time by email

    U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

    • Ardelyx Inc (NASDAQ:ARDX) shares jumped 81.2% to $2.21 in pre-market trading as the company said the FDA Advisory Committee voted 9-To-4 that the benefits of XPHOZAH outweigh its risks for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
    • Bath & Body Works, Inc. (NYSE:BBWI) climbed 22.3% to $38.09 in pre-market trading after the company reported better-than-expected Q3 results and raised FY22 earnings forecast.
    • SomaLogic, Inc. (NASDAQ:SLGC) surged 14.5% to $3.08 in pre-market trading. The company recently posted upbeat Q3 results and raised FY22 revenue guidance.
    • Companhia Energética de Minas Gerais (NYSE:CIG) shares gained 10.3% to $2.14 in pre-market trading following a 3% decline in the previous session.
    • Cartesian Growth Corporation (NASDAQ:GLBL) surged 10.1% to $9.48 in pre-market trading after dropping over 15% on Wednesday.
    • Atour Lifestyle Holdings Limited (NASDAQ:ATAT) gained 6.9% to $12.17 in pre-market trading. The company recently priced its IPO at $11 per share.
    • Cisco Systems, Inc. (NASDAQ:CSCO) climbed 4% to $46.16 in pre-market trading after the company reported better-than-expected Q1 results.

    Also check this out: Target Earnings Miss Estimates, Here's A Look At Recent Price Target Cuts By The Most Accurate Analysts .

    Get the next $ARDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDX
    $BBWI
    $CIG
    $CSCO

    CompanyDatePrice TargetRatingAnalyst
    Bath & Body Works Inc.
    $BBWI
    3/5/2026$23.00 → $25.00Market Perform
    Telsey Advisory Group
    Bath & Body Works Inc.
    $BBWI
    2/27/2026$17.00 → $23.00Market Perform
    Telsey Advisory Group
    Cisco Systems Inc.
    $CSCO
    2/18/2026Buy → Hold
    Erste Group
    Bath & Body Works Inc.
    $BBWI
    2/17/2026$25.00Buy → Neutral
    Citigroup
    Cisco Systems Inc.
    $CSCO
    1/26/2026$100.00In-line → Outperform
    Evercore ISI
    Bath & Body Works Inc.
    $BBWI
    1/14/2026$24.00Hold
    Jefferies
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Bath & Body Works Inc.
    $BBWI
    1/8/2026$21.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $ARDX
    $BBWI
    $CIG
    $CSCO
    SEC Filings

    View All

    SEC Form 10-K filed by Bath & Body Works Inc.

    10-K - Bath & Body Works, Inc. (0000701985) (Filer)

    3/12/26 4:21:47 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Bath & Body Works Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bath & Body Works, Inc. (0000701985) (Filer)

    3/4/26 7:17:38 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Bath & Body Works Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bath & Body Works, Inc. (0000701985) (Filer)

    3/3/26 4:30:37 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

    WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, announced the recipients of the 2026 Derek Forfang Patient Advocate Award: Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts. Established in 2025, this award honors Derek Forfang, a passionate patient advocate who suffered from chronic kidney disease (CKD) and passed away due to issues related to his disease in 2023. Derek worked tirelessly to improve the lives of patients, families and caregivers in the CKD community. Cand

    3/12/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

    WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the publication of data from its IBS-C clinical development program, "Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis" in Therapeutic Advances in Gastroenterology, an international, peer-reviewed, open-access journal focused on advancing clinical practice and research in digestive diseases. Tenapanor, branded as IBSRELA® (tenapanor), is a first-in-class retainagogue that is approved by the U.S. Food and Dru

    3/9/26 4:05:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ardelyx to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m. ET1x1 Meetings: Tuesday, March 10 To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the panel presentation will be available on the Ardelyx website for 30 days follo

    3/4/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Operations Subaiya Thimaya K. sold $134,410 worth of shares (1,744 units at $77.07) and covered exercise/tax liability with 1,715 shares, decreasing direct ownership by 2% to 156,693 units (SEC Form 4)

    4 - CISCO SYSTEMS, INC. (0000858877) (Issuer)

    3/12/26 5:46:20 PM ET
    $CSCO
    Computer Communications Equipment
    Telecommunications

    SVP & Chief Acctg Officer Wong Maria Victoria sold $42,725 worth of shares (551 units at $77.54) and covered exercise/tax liability with 299 shares, decreasing direct ownership by 3% to 27,957 units (SEC Form 4)

    4 - CISCO SYSTEMS, INC. (0000858877) (Issuer)

    3/12/26 5:45:52 PM ET
    $CSCO
    Computer Communications Equipment
    Telecommunications

    President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $260,621 worth of shares (41,666 units at $6.25), decreasing direct ownership by 1% to 1,836,153 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/25/26 4:13:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BBWI
    $CIG
    $CSCO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Bath & Body Works with a new price target

    Telsey Advisory Group reiterated coverage of Bath & Body Works with a rating of Market Perform and set a new price target of $25.00 from $23.00 previously

    3/5/26 7:43:54 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Bath & Body Works with a new price target

    Telsey Advisory Group reiterated coverage of Bath & Body Works with a rating of Market Perform and set a new price target of $23.00 from $17.00 previously

    2/27/26 8:06:42 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Cisco downgraded by Erste Group

    Erste Group downgraded Cisco from Buy to Hold

    2/18/26 9:41:39 AM ET
    $CSCO
    Computer Communications Equipment
    Telecommunications

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nash Sarah E bought $155,800 worth of shares (10,000 units at $15.58), increasing direct ownership by 4% to 285,522 units (SEC Form 4)

    4 - Bath & Body Works, Inc. (0000701985) (Issuer)

    11/25/25 4:16:41 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Director Symancyk James Kevin bought $350,550 worth of shares (22,500 units at $15.58), increasing direct ownership by 126% to 40,379 units (SEC Form 4)

    4 - Bath & Body Works, Inc. (0000701985) (Issuer)

    11/25/25 4:16:42 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Financials

    Live finance-specific insights

    View All

    Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year

    2/19/26 4:01:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bath & Body Works to Report Fourth Quarter and Fiscal 2025 Results on March 4, 2026

    COLUMBUS, Ohio, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) announced today that it plans to report its fourth quarter and fiscal 2025 financial results before market open on Wednesday, March 4, 2026. In conjunction with this report, the company will host a conference call at 8:30 a.m. ET during which Daniel Heaf, chief executive officer, and Eva Boratto, chief financial officer, will discuss the company's results and provide a business update. Supplemental materials will be posted approximately 90 minutes prior to the start of the conference call on the events and presentations page in the Investors section of the company's website at bbwinc.com. Investors and a

    2/18/26 8:30:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    CISCO REPORTS SECOND QUARTER EARNINGS

    SAN JOSE, Calif., Feb. 11, 2026 /PRNewswire/ --  News Summary: Double-digit top and bottom-line growth exceeding our guidance, with EPS growing faster than revenueRecord revenue of $15.3 billion, up 10% year over year; GAAP EPS of $0.80, up 31% year over year; and Non-GAAP EPS of $1.04, up 11% year over yearGAAP gross margin of 65.0% and Non-GAAP gross margin of 67.5%; GAAP operating margin of 24.6% and Non-GAAP operating margin of 34.6%, both above the high end of our guidance rangeAccelerating, double-digit growth in product orders across all geographies and robust growth ac

    2/11/26 4:05:00 PM ET
    $CSCO
    Computer Communications Equipment
    Telecommunications

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bath & Body Works Drives progress on the Consumer First Formula across innovation, brand elevation, and marketplace expansion and Reports Fourth Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    Delivers Q4 net sales and earnings per share results above guidanceFourth quarter net sales of $2.7 billion, down 2%. Earnings per diluted share of $1.99; Adjusted earnings per diluted share of $2.05Provides full-year 2026 guidance of net sales down 4.5% to down 2.5%, earnings per diluted share of $3.00 to $3.25; and adjusted earnings per diluted share of $2.40 to $2.65 COLUMBUS, Ohio, March 04, 2026 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) today reported fourth quarter and full-year 2025 results. Daniel Heaf, chief executive officer of Bath & Body Works, commented, "Our fourth quarter results exceeded the guidance we provided. Since launching the Consumer First Formula in

    3/4/26 6:55:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Bath & Body Works Outlines Strategic Transformation for Sustainable Growth and Reports 2025 Third Quarter Results

    Launches the Consumer First Formula with four strategic priorities to drive sustainable long-term growthThird-quarter net sales of $1.6 billion, down 1%. Earnings per diluted share of $0.37; Adjusted earnings per diluted share of $0.35Q4 and full-year 2025 guidance lowered reflecting current business trends and continuation of recent macro consumer pressures COLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) today reported third quarter 2025 results. Daniel Heaf, chief executive officer of Bath & Body Works, commented, "Today, we are excited to announce a comprehensive transformation plan to revitalize Bath & Body Works across brand, product, and market

    11/20/25 6:55:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Bath & Body Works Announces Key Leadership Appointments

    Maly Bernstein appointed Chief Commercial Officer to Strengthen Engagement and Performance Across All Channels Samantha Charleston appointed Chief Human Resources Officer to Align People Strategy with Business Priorities  COLUMBUS, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bath & Body Works, Inc. (NYSE:BBWI) today announced strategic leadership appointments to deepen expertise and strengthen capabilities required to execute transformation. Maly Bernstein has been appointed Chief Commercial Officer and Samantha Charleston has been appointed Chief Human Resources Officer, both effective Nov. 12.  "As we enter a new era for Bath & Body Works, we're building a next-generation leadership team w

    11/4/25 9:00:00 AM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ARDX
    $BBWI
    $CIG
    $CSCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

    SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

    11/14/24 4:08:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bath & Body Works Inc.

    SC 13G/A - Bath & Body Works, Inc. (0000701985) (Subject)

    11/14/24 1:28:29 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Bath & Body Works Inc.

    SC 13G/A - Bath & Body Works, Inc. (0000701985) (Subject)

    11/14/24 12:05:59 PM ET
    $BBWI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary